Latest Menorrhagia Stories
ABBOTT PARK, Ill. and SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain.
WAYNE, N.J., June 15 /PRNewswire/ -- Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc.
SAN DIEGO, May 24 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
SAN FRANCISCO, May 19 /PRNewswire/ -- Five presentations reporting the results of two placebo-controlled clinical trials evaluating Ferring Pharmaceuticals' LYSTEDA(TM) (tranexamic acid) tablets, a novel, first-in-class, non-hormonal therapy indicated for treatment of women with cyclic heavy menstrual bleeding (HMB), were presented at The American College of Obstetricians and Gynecologists 58th Annual Clinical Meeting in San Francisco, May 15-19, 2010.
NATICK, Mass., May 18 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval of its Genesys HTA(TM) System for the treatment of menorrhagia.
BEDFORD, Mass., May 11 /PRNewswire-FirstCall/ -- Hologic, Inc.
NEWPORT, Ky., May 10 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, today announced that it has tightly focused the strategic direction for the company on the pain management market.
Scientists described yesterday the discovery of a new drug, which is currently in Phase II clinical trials, designed to specifically target the root cause of painful menstrual cramps, not just the symptoms.
PEORIA, Ariz., Feb.
SALT LAKE CITY, Jan.
- To play, gamble.
- To impose upon; delude; trick; humbug; also, to joke; chaff.
- A deceitful game or trick; trickery; humbug; nonsense.